Madrigal Pharmaceuticals reported strong Q3 2026 results with Rezdiffra net sales reaching $431.3 million, a 50% increase year-over-year, and achieved its first profitable quarter. The drug surpassed $1.1 billion in year-to-date sales, reflecting rapid market growth and increased patient adoption. Madrigal is advancing its pipeline with a new Phase 3 MAESTRO-CSPH trial targeting well-compensated MASH cirrhosis (F4c), expected to start in early 2027, aiming to strengthen its leadership in this growing market. The company also announced the appointment of Dr. John C. Reed to its board and will present extensive clinical data at the upcoming AASLD Liver Meeting.
Madrigal Pharmaceuticals Q3 2026 results provide context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Nov 03, 2026 19:02 WIB: 74 of 150 US health stocks rose, 69 fell. Notable movers include ADMA at USD 11.35 (+2.62%), DYN at USD 16.86 (-2.54%), and DFTX at USD 32.82 (+2.34%).
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
